<SEC-DOCUMENT>0001437749-16-032028.txt : 20160516
<SEC-HEADER>0001437749-16-032028.hdr.sgml : 20160516
<ACCEPTANCE-DATETIME>20160516161104
ACCESSION NUMBER:		0001437749-16-032028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160516
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160516
DATE AS OF CHANGE:		20160516

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24477
		FILM NUMBER:		161653851

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20160516_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>dffn20160516_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA1 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>UNITED STATES</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Washington, D.C. 20549</B></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">__________________</FONT></P>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>FORM 8-K</B></FONT></P>
<P id=PARA8 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>CURRENT REPORT</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursuant to Section 13 or 15(d) of</B></FONT></P>
<P id=PARA11 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>the Securities Exchange Act of 1934</B></FONT></P>
<P id=PARA12 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">__________________</FONT></P>
<P id=PARA13 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of Report (Date of earliest event reported): May 16, 2016</B></FONT></P>
<P id=PARA15 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">___________________</FONT></P>
<P id=PARA16 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DIFFUSION PHARMACEUTICALS INC.</B></FONT></P>
<P id=PARA18 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Exact name of registrant as specified in its charter)</FONT></P>
<P id=PARA19 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL29  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA21 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA22 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>000-24477</B></FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA23 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>30-0645032</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA24 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(State or other jurisdiction of</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">incorporation)</FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA25 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Commission File</FONT></P>
<P id=PARA26 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number)</FONT></P></TD>
<TD style="WIDTH: 33%; VERTICAL-ALIGN: top">
<P id=PARA27 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(I.R.S. Employer</FONT></P>
<P id=PARA28 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Identification No.)</FONT></P></TD></TR></TABLE>
<P id=PARA30 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL38  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA32 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2020 Avon Court, #4</B></FONT></P>
<P id=PARA33 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Charlottesville, Virginia</B></FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA34 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA35 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>22902</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA36 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Address of principal executive offices)</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Zip Code)</FONT></P></TD></TR></TABLE>
<P id=PARA39 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">&nbsp;</FONT></P>
<P id=PARA40 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(434) 220-0718</B></FONT></P>
<P id=PARA41 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Registrant&#8217;s telephone number, including area code)</FONT></P>
<P id=PARA42 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA43 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Not applicable</B></FONT></P>
<P id=PARA44 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Former name or former address, if changed since last report)</FONT></P>
<P id=PARA45 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA46 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></P>
<P id=PARA47 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL48  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA111><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA112><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P></FONT></TD></TR></TABLE>
<P id=PARA49 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL50  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA113><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA114><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P></FONT></TD></TR></TABLE>
<P id=PARA51 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL52  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA115><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA116><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P></FONT></TD></TR></TABLE>
<P id=PARA53 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL54  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 18pt; VERTICAL-ALIGN: top">
<P id=PARA117><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: top">
<P id=PARA118><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P></FONT></TD></TR></TABLE>
<P id=PARA55 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="MARGIN-BOTTOM: 0px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA119.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK119  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR119  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM119  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR119  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA56 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA57 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 2.02 &#8211; Results of Operations and Financial Condition</B></FONT></P>
<P id=PARA58 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA59 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On May 16, 2016, Diffusion Pharmaceuticals Inc. issued a press release announcing its financial results for its first quarter ended March 31, 2016. A copy of that press release and the attached financial schedules are attached as Exhibit&nbsp;99.1 to this report and incorporated herein by reference.</FONT></P>
<P id=PARA60 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA61 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The information in this report (including Exhibit&nbsp;99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</FONT></P>
<P id=PARA62 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA63 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.01 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits </B></FONT></P>
<P id=PARA65 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d)&nbsp;&nbsp;&nbsp;Exhibits. </FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;<FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<TABLE id=TBL72  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA67 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exhibit&nbsp;Number</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">
<P id=PARA68 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="WIDTH: 85%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid">
<P id=PARA69 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 10%; VERTICAL-ALIGN: top">
<P id=PARA70 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1</FONT></P></TD>
<TD style="WIDTH: 5%; VERTICAL-ALIGN: bottom">&nbsp; </TD>
<TD style="WIDTH: 85%; VERTICAL-ALIGN: top">
<P id=PARA71 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Press release dated May 16, 2016, announcing financial results for the first quarter ended March 31, 2016 (furnished herewith).</FONT></P></TD></TR></TABLE>
<P id=PARA73.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK73  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR73  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM73  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR73  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA73.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA75 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>SIGNATURES</B></FONT></P>
<P id=PARA76 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA77 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P id=PARA78 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<TABLE id=TBL120  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 46%" vAlign=top width=617>
<P id=PARA120.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>Dated: May 16, 2016&nbsp;</P></TD>
<TD style="WIDTH: 2%" vAlign=top width=466 colSpan=2>
<P id=PARA120.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT><B>DIFFUSION PHARMACEUTICALS INC.</B></P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.3 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 46%" vAlign=top width=617>
<P id=PARA120.4 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 2%" vAlign=top width=23>
<P id=PARA120.5 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 36%" vAlign=top width=443>
<P id=PARA120.6 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.7 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 46%" vAlign=top width=617>
<P id=PARA120.8 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 2%" vAlign=top width=23>
<P id=PARA120.9 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 36%" vAlign=bottom width=443 noWrap align=left>
<P id=PARA120.10 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.11 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 46%; TEXT-ALIGN: left" vAlign=top width=617 align=left>
<P id=PARA120.12 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 2%; TEXT-ALIGN: left" vAlign=top width=23>
<P id=PARA120.13 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By: </FONT></P></TD>
<TD style="WIDTH: 36%; BORDER-BOTTOM: #000000 1px solid" vAlign=top width=443 noWrap align=left>
<P id=PARA120.14 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/ David G. Kalergis</FONT></P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.15 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 46%" vAlign=top width=617>
<P id=PARA120.16 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 2%" vAlign=top width=466 colSpan=2>
<P id=PARA120.17 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name:</FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>David G. Kalergis</P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.19 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 46%" vAlign=top width=617>
<P id=PARA120.20 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="WIDTH: 2%" vAlign=top width=466 colSpan=2>
<P id=PARA120.21 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title:</FONT>&nbsp;&nbsp; <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></FONT>Chief Executive Officer</P></TD>
<TD style="WIDTH: 16%" vAlign=top width=146>
<P id=PARA120.23 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA79 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA56 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA57 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA1 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 100%"><IMG src="diffu.jpg" width=148 height=66></TD></TR></TABLE>
<P id=PARA54 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></FONT></P>
<P id=PARA2 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;</P>
<P id=PARA3 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FOR IMMEDIATE RELEASE</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OTCQX: DFFN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA8 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: center; MARGIN-TOP: 0px; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Diffusion Pharmaceuticals Provides Corporate Highlights and Reports First Quarter 2016 Results</B></FONT></P>
<P id=PARA9 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Charlottesville, Virginia </B><B>(May </B><B>16</B><B>, </B><B>2016)</B> - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2016 and provided an overview of recent corporate highlights. The quarterly results will be filed shortly on Form 10-Q with the SEC.</FONT></P>
<P id=PARA11 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA12 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.35pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David Kalergis, Chairman and Chief Executive Officer of Diffusion, said, </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">"We are</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> pleased with the direction that we are heading following the merger with RestorGenex Corporation. We are continuing to expand our team and welcomed Tom Byrne as General Counsel. We also continue to advance our plan to expand the clinical development pipeline for TSC from GBM to first line pancreatic cancer."</FONT></P>
<P id=PARA13 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 5.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Corporate</B><B> </B><B>Highlights</B></FONT></P>
<P id=PARA15 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA16 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.5pt 0pt 5.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In January 2016, Diffusion Pharmaceuticals LLC completed a reverse merger with RestorGenex Corporation in an all-stock transaction. Following the close of the reverse merger, RestorGenex was renamed Diffusion Pharmaceuticals Inc. and its ticker symbol was changed to </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">"DFFN".</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA18 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.55pt 0pt 5.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In April 2016, Thomas Byrne joined Diffusion as General Counsel and transitioned from his prior positon on the Board of Directors. </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Mr. </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Byrne is continuing to oversee Diffusion&#8217;s intellectual property strategy, which he has directed since&nbsp;Diffusion was founded in 2001.</FONT></P>
<P id=PARA19 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.55pt 0pt 5.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.55pt 0pt 5.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>First Quarter 2016</B><B> Results</B></FONT></P>
<P id=PARA21 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA22 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.55pt 0pt 6.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development expenses were $2.4 million for the quarter ended March 31, 2016, compared to $732,000 for the quarter ended March 31, 2015. This increase was primarily a result of an increase in drug manufacturing costs and initiating the TSC pancreatic cancer program.</FONT></P>
<P id=PARA23 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA24 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.7pt 0pt 6.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.45pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General and administrative expenses were $3.9 million for the quarter ended March 31, 2016, compared to $459,000 for the quarter ended March 31, 2015. The increase was attributed to costs associated with the merger and operating as a public company, including corporate insurance, professional fees and financial reporting fees.</FONT></P>
<P id=PARA25 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA26 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.55pt 0pt 6.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss was $6.2 million for the quarter ended March 31, 2016, compared to a net loss of $1.2 million for the quarter ended March 31, 2015. The increase in the net loss was due primarily to higher expenses associated with the increased research and development expenses, and general and administrative expenses summarized above.</FONT></P>
<P id=PARA27 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA28 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents were $5.9 million for the quarter ended March 31, 2016, compared to</FONT> <FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">$2.0 million for quarter ended March 31, 2015.</FONT></P>
<P id=PARA30 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 100%"><IMG src="diffu2.jpg" width=116 height=70></TD></TR></TABLE>
<DIV id=PGBK58  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR58  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM58  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR58  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA58.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About </B><B>Diffusion Pharmaceuticals Inc.</B></FONT></P>
<P id=PARA32 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA33 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.65pt 0pt 6pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diffusion Pharmaceuticals Inc.&nbsp;is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead drug, <I>trans sodium crocetinate </I>(TSC), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. TSC targets the cancer&#39;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects.</FONT></P>
<P id=PARA34 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA35 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.2pt 0pt 6.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care. The</FONT></P>
<P id=PARA36 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.65pt 0pt 6.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">U.S. Food and Drug Administration has agreed upon the design of a Phase 3 trial in newly diagnosed GBM. Additional planned studies include a Phase 2 trial in pancreatic cancer and a study in brain metastases. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in our preclinical and clinical studies.&nbsp;Diffusion believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard- of-care treatments of other life-threatening cancers. We also believe that TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases.</FONT></P>
<P id=PARA37 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA38 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.75pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Forward-Looking</B><B> Statements</B></FONT></P>
<P id=PARA40 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA39 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.05pt 0pt 6.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.95pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company&#39;s plans, objectives, expectations and intentions with respect to future operations and products, the potential of the</I></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I> </I></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>combined company&#39;s technology and product candidates, the anticipated timing of future clinical trials, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," &#39;&#39;plans," &#39;&#39;possibility, </I>" <I>"potential," "future," "expects, </I>" <I>"anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations</I><I> </I><I>of</I><I> </I><I>such</I><I> </I><I>words</I><I> </I><I>and</I><I> </I><I>the</I><I> </I><I>use</I><I> </I><I>of future</I><I> </I><I>dates</I></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>.</I><I> </I></FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>Forward-looking</I><I> </I><I>statements</I><I> </I><I>by</I><I> </I><I>their</I><I> </I><I>nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company&#39;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include; general business and economic conditions; the company&#39;s need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. All forward-looking statements in this news release speak only as of the date of this news release and are based on Diffusion management&#39;s current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking</I><I> </I><I>statement, whether</I><I> </I><I>as</I><I> </I><I>a</I><I> </I><I>result</I><I> </I><I>of</I><I> </I><I>new</I><I> </I><I>information,</I><I> future</I><I> </I><I>events</I><I> </I><I>or</I><I> </I><I>otherwise.</I></FONT></P>
<P id=PARA41 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>&nbsp;</I></FONT></P>
<P id=PARA43 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA42 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Diffusion </B><B>Pharmaceuticals Contacts</B></FONT></P>
<P id=PARA44 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA45 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David Kalergis</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Executive Officer Diffusion Pharmaceuticals Inc.</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(434) 220-0718</FONT></P>
<P style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">dkalergis@diffusionpharma.com</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA49 style="TEXT-ALIGN: left; MARGIN: 0pt 75.3% 0pt 8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.45pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stephanie Carrington ICR Inc.</FONT></P>
<P id=PARA50 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(646) 277-1282</FONT></P>
<P id=PARA51 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stephanie.Carrington@icrinc.com</FONT></P>
<P id=PARA52 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA53 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>diffu2.jpg
<TEXT>
begin 644 diffu2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !& '0# 2(  A$! Q$!_\0
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M7@[5++2O%::/;WU[->QEM(OM5AN9;.$1@'SXF%L,S*P&VYMV56#/L /$H_\
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M!VLI7(/0?!O]G+PY\#-6UJ^T1;H7?B"*QBOGE9 DGV2W%O$RQHJQQDH,L$4
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..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>diffu.jpg
<TEXT>
begin 644 diffu.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !" )0# 2(  A$! Q$!_\0
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MA,R%P4P-IS\N!C% [GXK?\'CUU';?$3X'>9(B9T?6L;F S^\M*_07XRRJ/\
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M4_$GAN"WN+RPU#3X;B.:]LK:=X4FC:\C)^SRJLBP+CR_,8#[4^('_!-;X/\
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M&CX6N=!\9^/_  ):>&[HS7NO6UCJ-A):Q2/;S(MO(LD<P"%?.<,&,:N?2/\
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$% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
